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Tuberculosis (TB) is the deadliest bacterial disease in the world. New therapeutic agents are urgently
needed to replace existing drugs for which resistance is a significant problem. DNA topoisomerases are
well-validated targets for antimicrobial and anticancer chemotherapies. Although bacterial
topoisomerase I has yet to be exploited as a target for clinical antibiotics, DNA gyrase has been
extensively targeted, including the highly clinically successful fluoroquinolones, which have been
utilized in TB therapy. Here, we review the exploitation of topoisomerases as antibacterial targets and
summarize progress in developing new agents to target DNA topoisomerase I and DNA gyrase from
Mycobacterium tuberculosis.Introduction
Although the information content of DNA is essentially indepen-
dent of how the DNA is knotted or twisted, the access to this
information depends on the topology of the DNA. DNA topoi-
somerases are ubiquitous enzymes that maintain the topological
homeostasis within the cell during these DNA transaction pro-
cesses [1–3]. In the words of James C. Wang, ‘DNA topoisomerases
are the magicians of the DNA world’ [4]; however, unlike the
sleight of hand used by a magician, topoisomerases rely on the
elegant chemistry of transesterification. Depending on their
mechanism of action, these enzymes are broadly classified as type
I (which make transient single-stranded breaks in DNA) and type
II (transient double-stranded breaks). The enzymes are further
subdivided into types IA and IB, distinguished by whether the
transient covalent bonds are to the 50- or 30-phosphate, respec-
tively, and types IIA and IIB, which differ in mechanistic and
evolutionary aspects [5]. Given their functional importance, ev-
ery species has at least one enzyme from each type. Although the
presence of more than one topoisomerase from each type allows
for a division of labor for supercoiling, relaxation, knotting/
unknotting, and catenation/decatenation, this redundancy alsoPlease cite this article in press as: Nagaraja, V. et al. DNA topoisomerase I and DNA gy
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instance, in Escherichia coli, there are four topoisomerases: two
type I [topoisomerase (topo) I and topo III] and two type II (DNA
gyrase and topo IV). In vitro, all four enzymes are capable of DNA
relaxation, whereas, in vivo, their roles tend to be more special-
ized, for example, gyrase introduces negative supercoils, whereas
topo IV is responsible for decatenation following replication [6];
these functions are critical for cell survival. By contrast, the
Mycobacterium tuberculosis (Mtb) genome encodes a single type I
(topo I; gene = Rv3646c) and a single type II topoisomerase [gyr-
ase; genes = Rv0006 (gyrA) and Rv0005 (gyrB)] [7], which take care
of the entire burden of decatenation, relaxation, and supercoil-
ing. In organisms with additional topoisomerases, not all the
topoisomerases are essential for cell survival. For example, in E.
coli, topo I is not necessarily essential [8], whereas saturation
mutagenesis studies suggested the essentiality of Mtb topo I
(MttopoI) [9]. This essentiality is confirmed by generating condi-
tional knockdown strains, wherein the intracellular level of the
enzyme is downregulated [10]. The minimal composition of the
topoisomerases in the Mtb genome necessitates the enzymes to
carry out additional functions in vivo. Previous studies of myco-
bacterial topoisomerases have revealed these additional func-
tions as well as their distinct features [11–18].rase as targets for TB therapy, Drug Discov Today (2016), http://dx.doi.org/10.1016/
license (http://creativecommons.org/licenses/by/4.0/).
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FIGURE 1
Topoisomerase reaction mechanisms. (a) Bacterial topoisomerase I (topo I) reaction cycle: the multistep reaction is initiated with the interaction and binding of the
enzyme to negatively supercoiled DNA. DNA binding is followed by the first transesterification reaction in which the nucleophilic attack by the tyrosine of the
active site on the phosphodiester backbone results in the formation of the topo I-DNA covalent complex and separation of the domains to form an enzyme–DNA
gate. Next, the intact strand of DNA is passed through this enzyme–DNA gate, resulting in a change in linking number. After strand passage, during the second
transesterification reaction, the separated domains close and the 30-hydroxyl group targets the phosphotyrosine covalent adduct with a nucleophilic attack,
resulting in the resealing of the cleaved DNA strand. During the reaction cycle, the various domains of the enzyme open and close like a clamp, facilitating the
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NDNA cleavage: the Achilles’ heel of the topoisomerase
mechanism
The reaction mechanism of type IA topoisomerases involves a
series of coordinated steps. The reaction cycle, depicted in
Fig. 1a, shows the noncovalent binding of the enzyme to the
substrate, followed by a transesterification reaction involving a
nucleophilic attack on the phosphodiester backbone by the ac-
tive-site tyrosine, resulting in the formation of a phosphotyrosine
covalent adduct. The intact strand of DNA is passed through the
cleaved DNA followed by another transesterification reaction in-
volving nucleophilic attack by the free 30-OH on the phosphotyr-
osine covalent adduct resulting in the resealing of the cleaved DNA.
A cleavage–religation equilibrium between the two transesterifica-
tion reactions is an important feature of the overall reaction.
Perturbation of this equilibrium can lead to the accumulation of
enzyme–DNA covalent adducts, which are potentially cytotoxic.
Topoisomerase poisons are molecules that perturb the cleavage–
religation equilibrium, resulting in the accumulation of enzyme–
DNA covalent adducts [19]. The cleavage of the DNA is a vulnerable
step during the reaction mechanism of the enzyme that could be
exploited to develop inhibitors that can act as topoisomerase
poisons.
In the case of type II topoisomerases, such as bacterial gyrases,
the reaction cycles proceed via transient double-stranded breaks in
DNA. In the general case, as represented by eukaryotic topo II and
bacterial topo IV, the dimeric enzyme binds two segments of DNA,
a G (or gate) segment and a T (or transported) segment. Double-
stranded cleavage of the G segment facilitates passage of the T
segment through the G segment (and, thus, through the protein
interfaces of the dimeric enzyme), in a reaction driven by the
binding and hydrolysis of ATP [20]. Gyrase is a special case of this
mechanism (Fig. 1b) in which the G and T segments are colinear
and the strand-passage event leads to the introduction of negative
supercoils [1]. As with the type I enzymes, cleavage of the DNA
(double stranded in this case) is a vulnerability that can be poten-
tially exploited to develop inhibitors [21].
Thus, one of the most desired classes of molecule that target
topoisomerases are topoisomerase poisons [19]. However, until
recently, no such molecules had been discovered for bacterial type
I enzymes, although it has been genetically and chemically vali-
dated as an anti-TB target [22]. By contrast, several molecules
target type II topoisomerases (bacterial and eukaryotic) and type
IB enzymes (typically found in eukaryotes). In the case of eukary-
otic type IB enzymes, camptothecin [23,24] and its various deri-
vatives target human topo I. Although an inhibitor that acts in a
similar fashion is desired for type IA topoisomerases, catalytic
inhibitors of the enzyme might also be useful in those organisms
harboring a single type IA topoisomerase. DNA gyrase has been
extensively exploited as a target for the development of antibac-
terial compounds (discussed below), prominent among themPlease cite this article in press as: Nagaraja, V. et al. DNA topoisomerase I and DNA gy
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formation of the topo I-DNA gate and religation, respectively. (b) Model for the me
follows: GyrB-NTD, dark blue; GyrB-TOPRIM domain, red; GyrB-tail, green; GyrA-NTD
and purple, respectively. (i) The subunits and DNA in their free states in solution; star
ATP-binding pocket. (ii) The G segment binds between GyrA-NTD and GyrB-TOPRIM,
in a positive crossover. (iii) ATP is bound, closing the GyrB clamp (GyrB-NTD) and ca
one ATP molecule allows GyrB to rotate, the DNA gate to widen, and the transpor
through the C gate, and the G segment is religated. The hydrolysis of the remain
Abbreviations: CTD, C-terminal domain; NTD, N-terminal domain; TOPRIM, topoisobeing the fluoroquinolones, which are one of the most effective
cellular poisons, arresting the gyrase reaction after DNA cleavage
leading to the generation of double-strand breaks [25,26].
Inhibitors of MttopoI
In work by the Nagaraja lab, in part supported by the MM4TB
consortium (www.mm4tb.org), has pursued the design of proof-of-
principle inhibitors for MttopoI. Biochemical characterization of
topo I from both Mycobacterium smegmatis [11] as well as Mtb [27]
revealed the site-specific nature of the enzyme, which recognizes a
hexameric sequence, CG/TCT#TC/G (where # indicates the site of
cleavage) [16]; these sites are referred to as ‘strong topoisomerase
sites’ (STS). The binding as well as the cleavage reaction is sequence
specific and, therefore, enabled the design of oligonucleotide sub-
strates that can inhibit the DNA relaxation reaction. Incubation of
the enzyme with the oligonucleotides harboring the STS causes the
DNA-binding site of the enzyme to be occluded for the binding of
negatively supercoiled DNA, leading to the inhibition of the DNA
relaxation reaction [16]. Next, monoclonal antibodies (mAbs) were
developed that specifically inhibit the mycobacterial topo I, an
approach that had been used previously to develop specific inhi-
bitors of mycobacterial gyrase [28]. Apart from being used as tools
to understand the finer details of the reaction, these mAbs could
also serve as valuable start points for the development of small-
molecule inhibitors against mycobacterial topo I. One of the mAbs,
1E4F5, was especially interesting owing to its mechanism of action.
Depending on the order of addition of the mAb, it could inhibit the
reaction at multiple steps. Pre-incubation of the mAb with the
enzyme led to the inhibition of the DNA-binding ability, while
incubation of the mAb with a preformed topo I-DNA complex led
to the formation of a mAb-topo I-DNA ternary complex [29]. This
mAb was shown to close the clamp of the enzyme, thus stimulating
the second transesterification step. Another mAb, 2F3G4, affected
the cleavage–religation equilibrium of the reaction, leading to the
accumulation of the topo I-DNA covalent complex; thus, 2F3G4
behaves like a topoisomerases poison [30].
All topoisomerases, irrespective of their class, transiently cleave
DNA during their reaction cycle. As discussed, this step has been
extensively exploited in the development of antibacterial as well as
anticancer agents, which target gyrase and eukaryotic topoisome-
rases, respectively. Thus, it is surprising that there is a dearth of such
small molecules that target bacterial topo I. However, in the recent
past, several studies have addressed this shortcoming. Using an
high-throughput screening (HTS) assay based on SOS induction in
E. coli, a phenanthrene compound, stephenanthrene, was identi-
fied as a bacterial topo I poison [31]. More recently, derivatives of
bolden, seconeolitsine, and N-methyl-seconeolitsine (Fig. 3) were
also identified to target the DNA relaxation activity of bacterial
topo I [32]. Apart from derivatives of bolden, bisbenzimidazole
analogs of Hoechst dyes, 3,4-dimethoxyphenyl bisbenzimidazolerase as targets for TB therapy, Drug Discov Today (2016), http://dx.doi.org/10.1016/
chanism of DNA supercoiling by DNA gyrase. Gyrase domains are colored as
, orange; GyrA-CTD, light blue. The G and T DNA segments are colored black
s indicate the active site residues for DNA cleavage and the circle indicates an
 at the dimer interface, and the GyrA CTDs wrap DNA to present the T segment
pturing the T segment; the G segment is transiently cleaved. (iv) Hydrolysis of
t of the T segment through the cleaved G segment. (v) The T segment exits
ing ATP molecule resets the enzyme. Reprinted, with permission, from [73].
merase primase domain.
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have been identified as potential inhibitors of topo I (Fig. 3). DMA
was shown to act as a topoisomerase poison, both in vitro as well as,
to a limited extent, in whole-cell assays [33]. More recently, analogs
of bisbenimidazoles, such as bisbenzimidazole 12b (Fig. 3), were
shown to be an improvement over DMA in terms of IC50 values and
having lower MICs among the compounds tested against several
E. coli strains [35].
Exploring natural product chemical space yielded anziaic acid
(Fig. 3) derived from the lichen Hypotrachyna sp. and shown to be a
dual inhibitor of type IA as well as type IIA topoisomerases. Anziaic
acid was demonstrated to act like a topoisomerase poison [36].
However the molecule exhibited toxicity toward human pulmonary
artery endothelial cells, possibly because of its dual-targeting ability
[36]. Another small molecule identified by exploring the natural
product spectrum was 2,4-diiodoemodin (Fig. 3), a haloemodin
derived from the bioactive natural product emodin. This molecule
is a dual inhibitor of topoisomerase I and DNA gyrase [37]. The dual
inhibition capability could have important implications in suppres-
sing resistance in pathogenic bacteria, such as Mtb, which has only
two topoisomerases.
An alternate approach was used to find small-molecule inhibi-
tors for MttopoI. Initially, a structural model of the enzyme was
generated to screen in silico a large number of molecules followed
by testing these molecules for enzyme inhibition directly (Fig. 2).
Using this target-based approach, three molecules were shown to
inhibit the DNA relaxation activity of MttopoI as well as to affect
the growth of Mtb cells in a whole-cell assay (Fig. 3). One of the
three molecules, m-AMSA (amsacrine; Fig. 3), is a well-known type
IIA topoisomerases poison [38]. The other two molecules, imipra-
mine and norclomipramine (Fig. 3), are used clinically as anti-
depressants [39,40]. These two molecules inhibited the DNAPlease cite this article in press as: Nagaraja, V. et al. DNA topoisomerase I and DNA gy
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(a)
FIGURE 2
Structural model of Mycobacterium tuberculosis (Mtb) topoisomerase I (MttopoI). S
sphere), and the superimposition of the crystal structure shown in yellow with the h
structure and the model of the enzyme are outside the docking region.
4 www.drugdiscoverytoday.comrelaxation activity at lower concentrations [41]. Notably, they
arrested the reaction and formed cleavage complexes with a higher
efficiency and were found to be bactericidal. Moreover, a decrease
in the MIC for the compounds in cells overexpressing topo I
validated topo I as the intracellular target and their action as
intracellular topo I poisons [41]. Although their potency was
not comparable to that of fluoroquinolones, they are the most
potent anti-topo I inhibitors reported so far. This study also
highlighted the potential to repurpose clinically relevant com-
pounds to target mycobacterial topo I [38]. Recent efforts starting
from a polyamine scaffold have led to the identification of four
more compounds that inhibit the DNA relaxation activity of
MttopoI and also affect the growth of mycobacterial cells; howev-
er, none of these molecules acts as a topoisomerase poison [42].
To summarize, the search for potent inhibitors of bacterial type
IA enzymes has begun, with some indications of success. Although
these efforts using different approaches have yielded a few hits, the
efficacy of these molecules in in vivo models of infection needs to
be tested. Such studies are underway with imipramine. Clearly,
more efforts are needed to develop better inhibitors using a variety
of approaches and a combination of strategies, including synthesis
of new derivatives from the early leads. Perhaps a high-throughput
assay for screening a large number of compounds in a short time
might not be out of place. The X-ray structure of the truncated
MttopoI published recently is a way forward in finding potent
inhibitors of the enzyme [43]. The availability of this structure will
provide major insights into the rational design of small-molecule
inhibitors of MttopoI.
Inhibitors of M. tuberculosis gyrase
In contrast to topo I, Mtb gyrase (Mtgyrase) has been extensively
exploited as a target for potential antibacterials. This is in partrase as targets for TB therapy, Drug Discov Today (2016), http://dx.doi.org/10.1016/
(b)
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tructural model of Mttopol (a) with the imipramine docking region (filled
omology model colored by atom (b); the differences highlighted between the
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FIGURE 3
Small-molecule inhibitors of topoisomerase I.
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antibiotics effective against a range of pathogenic bacteria [21]. In
addition, the extensive structural information on gyrase from
several bacteria, including Mtb [44–48], has potentiated in silico
methods for developing new gyrase-specific inhibitors; examples
of this approach are given below. Perhaps surprisingly, there is
currently no complete crystal structure of gyrase (A2B2) for any
organism. However, it is possible to build such a structure (in this
case for Mtgyrase) using available information from domains and
protein fragments (Fig. 4).
The most successful gyrase-targeted antibacterial agents are the
fluoroquinolones and several of these compounds have proved
efficacious against TB; these include gatifloxacin and moxifloxacin
(Fig. 5) [49–51], which are being evaluated both for first-line
therapeutics and second-line therapy for multi-drug resistant
(MDR) and extensively drug-resistant (XDR) TB (Fig. 5). In relation
to moxifloxacin, which is currently the most promising fluoro-
quinolone targeted to TB, the results from a recent large-scale
Phase 3 trial demonstrated that this drug could not be substituted
for isoniazid or ethambutol in a 4-month treatment regimen
[52,53]. However, it is clear that moxifloxacin will still have an
important role in TB therapy, particularly for MDR-TB.
Work on understanding quinolone action on Mtgyrase and
developing new inhibitors has been greatly assisted by X-ray
crystallography. The structures of the GyrA N-terminal domainPlease cite this article in press as: Nagaraja, V. et al. DNA topoisomerase I and DNA gy
j.drudis.2016.11.006(NTD) and the catalytic core [C-terminal domain (CTD) of GyrB
fused to the GyrA NTD] were initially determined [47,48]. Given
that these regions contain amino acid residues that interact with
quinolones, this gave some initial insight into drug–protein
interactions. Work on gyrase and topo IV from other organisms
revealed crystal structures with bound DNA and quinolones,
specifically, the structure of the catalytic core fusion of Strepto-
coccus pneumoniae topo IV complexed with moxifloxacin and
clinafloxacin [54], the structure of the catalytic core fusion of
Staphylococcus aureus gyrase complexed with ciprofloxacin [55],
and the catalytic core fusion of Acinetobacter baumannii topo IV
complexed with moxifloxacin [56]. These structures provided
molecular insight into the mechanism of inhibition by quino-
lones. In more recent work, structures have been obtained for
the Mtb GyrB-GyrA catalytic core with moxifloxacin, gatifloxa-
cin, and other quinolones [45]. These structures highlight the
details of Mtgyrase–quinolone–DNA interactions and how these
differ from those seen in other organisms, and will potentiate
the development of new compounds with increased potency
against TB.
However, despite success in understanding the molecular basis
of gyrase–quinolone–DNA interactions, resistance to quinolones is
a serious problem in TB and other bacterial infectious diseases.
Therefore, we need to develop other agents that can avoid the
resistance issues of existing antibiotics.rase as targets for TB therapy, Drug Discov Today (2016), http://dx.doi.org/10.1016/
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FIGURE 4
Structural model of Mycobacterium tuberculosis DNA gyrase (Mtgyrase). The figure shows space-filling (a) and ribbon (b) representations of Mtgyrase. The models
were made by taking existing crystal structures (5BS8, 1ZVU, and 3ZKB) and using the program COOT to assemble a model of the A2B2 complex. Domains are
colored as follows: GyrB-NTDs, pink and sea-green; GyrB-CTDs, gold and gray; GyrA-NTDs, coral and ice blue; GyrA-CTDs, purple and pale brown. DNA is in a green
ribbon representation. Abbreviations: CTD, C-terminal domain; NTD, N-terminal domain.
R
eview
s
G
E
N
E
T
O
S
C
R
E
E
NIn work supported by the MM4TB consortium, we investigated a
large number of compounds for their potential as new gyrase-
targeted antibiotics (unpublished data). Specifically, we were seek-
ing compounds that show efficacy against Mtb (growing and/or
dormant) and that inhibit the gyrase supercoiling reaction. Ideal-
ly, the compounds should have a good IC50 against gyrase
(<50 mM) and, if possible, should stabilize the cleavage complex
but not show crossresistance to quinolones. We received >2000
compounds (mostly synthetic) from other partners and evaluated
their efficacy versus Mtgyrase. We found >60 compounds with
IC50 <50 mM and evidence for compounds with new modes of
action; fully characterizing these compounds and establishing
their prospects as potential TB agents is the subject of ongoing
work.
In connection with the MM4TB project, we also investigated
naphthoquinone natural products as inhibitors of Mtgyrase.
Extracts from the South African ‘toothbrush’ tree, Euclea nata-
lensis, have been extensively used in traditional medicine and
were found to be active against Mtb [57]. One active component
of this extract was shown to be the naphthoquinone diospyrin
(Fig. 5) [58], which was found to be an inhibitor of DNA gyrase
[60]. Moreover, diospyrin and other naphthoquinones were
found to have a novel mechanism of action, binding to the
GyrB-NTD, but not at the ATPase site [59]. The molecular details
of this binding pocket remain to be determined. Interestingly,
naphthoquinone compounds have also been found to inhibit
Mtb ThyX, an essential thymidylate synthase [60]. Whereas some
compounds, such as 7-methyljuglone (Fig. 5), inhibit both
enzymes, most affect ThyX without inhibiting gyrase. This sug-
gests that the pharmacophores for the two targets (ThyX and
GyrB) are distinct [60].
Other research groups have been developing new TB agents
targeted to gyrase, particularly using in silico methods based on the
new and emerging structural information on Mtgyrase. The crystal
structure of the GyrB-NTD (ATPase domain) of E. coli gyrasePlease cite this article in press as: Nagaraja, V. et al. DNA topoisomerase I and DNA gy
j.drudis.2016.11.006
6 www.drugdiscoverytoday.comcomplexed with an ATP analog, and that of the 24-kDa GyrB
N-terminal subdomain with novobiocin [61,62], paved the way
for structure-based drug design based around these ligand pockets.
More recently, the corresponding structure (GyrB-NTD) for Mtgyr-
ase has further promoted such work [44]. The group of Sriram
investigated a large number of inhibitors of Mtgyrase, following
computationally based approaches [63,64]; for example, using this
methodology, 28 2-amino-5-phenylthiophene-3-carboxamides
were synthesized, the best one having an MIC against Mtb of
4 mM and an IC50 for Mtgyrase supercoiling of 0.8 mM [65]. In
another study, 48 quinoline-aminopiperidine-based urea and
thiourea derivatives were designed, synthesized, and evaluated;
the best compound had an MIC against M. tuberculosis of 3.5 mM
and an IC50 for Mtgyrase supercoiling of 0.7 mM [66]. Similar work
has been carried out with substituted benzofuran compounds and
pyrrolamides [67,68].
Astra-Zeneca have also published a series of papers describing
compounds that target the ATP-binding site. Aminopyrazina-
mides (Fig. 5) were identified from a HTS using the M. smegmatis
GyrB ATPase reaction [69]. A crystal structure of one of these
compounds complexed with the M. smegmatis GyrB-NTD revealed
the specifics of ligand–protein interactions in this case. Aside from
having good IC50, these compounds also show promising MICs.
In silico approaches led to thiazolopyridine ureas [70] and thiazo-
lopyridone ureas [71] as compounds that also had good activities
and properties.
Although a significant amount of effort has been expended on
discovering new Mtgyrase inhibitors, most of this has centered on
the ATP- and quinolone-binding sites. Exceptions to this are the
naphthoquinone studies described above [59,60] and work from
GSK [72], which identified novel bacterial topoisomerase inhibi-
tors (NBTIs) with activity against Mtgyrase and that lack cross-
resistance to fluoroquinolones (Fig. 5). More inhibitors acting at
sites different from the well-known binding pockets would be
desirable.rase as targets for TB therapy, Drug Discov Today (2016), http://dx.doi.org/10.1016/
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FIGURE 5
Small-molecule inhibitors of Mycobacterium tuberculosis DNA gyrase (Mtgyrase): (a) fluoroquinolones; (b) naphthoquinones; (c) a representative
aminopyrazinamide from Astra-Zeneca [69], and a representative novel bacterial topoisomerase inhibitor (NBTI) from GSK [72].
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There is no question that topoisomerases have been effective
targets both for anticancer and antibacterial chemotherapy and
there appears to be every reason to persist in the search for new
agents that target MttopoI and Mtgyrase. These two enzymes can
be regarded separately. In the case of MttopoI, it can be regarded as
a ‘new’ target that remains to be exploited clinically. However,
given the urgent need to find new antibacterial agents and the
depth of knowledge about this enzyme, it is justifiable to expend
more effort in seeking new inhibitors. In the case of Mtgyrase, the
success of fluoroquinolones and the existence of other exploitable
ligand-binding pockets in gyrase suggest that work on seeking new
gyrase-specific inhibitors will continue to be important. Whether
these searches are target-based or follow phenotypic screens is aPlease cite this article in press as: Nagaraja, V. et al. DNA topoisomerase I and DNA gy
j.drudis.2016.11.006moot point; the evidence from recent studies suggests that both
approaches are valid. In any case, it is probably that combined
academic and pharma efforts will be needed to achieve success.
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